tiprankstipranks
Trending News
More News >
Japan Tissue Engineering Co., Ltd. (JP:7774)
:7774
Japanese Market

Japan Tissue Engineering Co., Ltd. (7774) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Japan Tissue Engineering Co., Ltd.

(7774)

Rating:58Neutral
Price Target:
Japan Tissue Engineering Co., Ltd. scores moderately due to a strong balance sheet and technical momentum. However, profitability and cash flow concerns, alongside a negative P/E ratio, weigh on the overall assessment. The company's financial stability provides a foundation, but the lack of earnings growth and cash flow issues are key risks.

Japan Tissue Engineering Co., Ltd. (7774) vs. iShares MSCI Japan ETF (EWJ)

Japan Tissue Engineering Co., Ltd. Business Overview & Revenue Model

Company DescriptionJapan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.
How the Company Makes MoneyJ-TEC generates revenue through the sale of its tissue-engineered products, which are used in medical treatments and procedures. The company's primary revenue streams come from the commercial sales of its cultured tissue products to hospitals and medical institutions. Additionally, J-TEC is involved in collaborative research and development projects with academic institutions and other corporations, which may provide additional funding and revenue opportunities. The company also invests in intellectual property development and may earn income through licensing agreements or partnerships with other entities in the regenerative medicine space.

Japan Tissue Engineering Co., Ltd. Financial Statement Overview

Summary
Japan Tissue Engineering Co., Ltd. presents a mixed financial picture. While the balance sheet is strong with no debt and high equity, profitability challenges are evident with negative net income and EBIT margins. The cash flow statement highlights potential cash management issues, transitioning from positive to zero free cash flow.
Income Statement
45
Neutral
The company has shown erratic revenue patterns with recent declines in revenue from the annual to TTM period. Gross profit margins remain relatively high, but negative net income and EBIT margins indicate ongoing profitability challenges. Despite previous growth, the most recent TTM figures show significant financial distress.
Balance Sheet
70
Positive
The balance sheet reflects strong equity with no debt, which indicates financial stability and low leverage. The high equity ratio suggests the company is well-capitalized. However, the consistent negative net income impacts return on equity, which remains negative.
Cash Flow
40
Negative
The cash flow statement shows a lack of positive free cash flow and operating cash flow, which could concern stakeholders. The transition from positive free cash flow in the previous year to zero in the TTM period underlines potential cash management issues.
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue2.44B2.46B2.51B2.03B2.10B2.26B
Gross Profit1.49B1.47B1.69B1.14B1.26B1.16B
EBITDA12.67M-76.02M278.56M-597.00M-374.00M-359.89M
Net Income-153.61M-255.30M143.17M-729.32M-497.89M-466.62M
Balance Sheet
Total Assets6.45B6.51B6.99B6.88B7.60B8.12B
Cash, Cash Equivalents and Short-Term Investments4.07B3.89B4.27B4.13B4.93B5.28B
Total Debt0.000.000.00133.00K936.00K1.74M
Total Liabilities717.83M687.95M908.43M946.15M931.66M954.78M
Stockholders Equity5.73B5.83B6.08B5.94B6.67B7.16B
Cash Flow
Free Cash Flow0.00-224.48M938.00K-798.60M-342.48M-473.98M
Operating Cash Flow0.00-148.37M274.14M-622.60M-225.25M-399.59M
Investing Cash Flow0.00-232.53M-242.23M1.12B-116.48M125.89M
Financing Cash Flow0.00-3.00K-134.00K-803.00K-823.00K-1.30M

Japan Tissue Engineering Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price567.00
Price Trends
50DMA
601.32
Negative
100DMA
535.46
Positive
200DMA
514.99
Positive
Market Momentum
MACD
-4.96
Positive
RSI
42.06
Neutral
STOCH
8.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7774, the sentiment is Neutral. The current price of 567 is below the 20-day moving average (MA) of 597.70, below the 50-day MA of 601.32, and above the 200-day MA of 514.99, indicating a neutral trend. The MACD of -4.96 indicates Positive momentum. The RSI at 42.06 is Neutral, neither overbought nor oversold. The STOCH value of 8.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7774.

Japan Tissue Engineering Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
¥9.68B25.09
7.98%24.12%
58
Neutral
¥23.03B
-2.34%-278.32%
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
49
Neutral
¥17.82B179.65
8.46%49.97%
47
Neutral
¥19.01B
-100.00%-1079.89%
45
Neutral
¥16.22B
-4.04%-0.88%
37
Underperform
¥44.28B
374.19%35.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:7774
Japan Tissue Engineering Co., Ltd.
567.00
-133.00
-19.00%
JP:4593
Healios KK
423.00
253.00
148.82%
JP:4599
StemRIM Inc.
306.00
-115.00
-27.32%
JP:4978
ReproCELL Inc.
188.00
50.00
36.23%
JP:7096
StemCell Institute
945.00
-641.65
-40.44%
JP:7776
CellSeed Inc.
468.00
-172.00
-26.88%

Japan Tissue Engineering Co., Ltd. Corporate Events

Japan Tissue Engineering Co., Ltd. Reports Third Quarter Financial Results and Adjusted Forecast
Jan 31, 2025

Japan Tissue Engineering Co., Ltd. reported a decrease in net sales and net income for the third quarter of FY2024 compared to the previous year, reflecting ongoing financial challenges. The company has revised its forecasts for FY2024, indicating a cautious outlook amid a competitive market environment, which could have implications for its stakeholders and market position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025